Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference22 articles.
1. CT001 Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a phase I trial;Hodi;Cancer Res,2016
2. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study;Gettinger;J Clin Oncol Off J Am Soc Clin Oncol,2018
3. Overall survival and long-term safety of nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer;Gettinger;J Clin Oncol Off J Am Soc Clin Oncol,2015
4. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment;Robert;J Clin Oncol Off J Am Soc Clin Oncol,2017
5. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies;Lebbe;Ann Oncol,2014
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of cross‐line anti‐programmed death 1/programmed cell death‐ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study;Health Science Reports;2024-05
2. Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer;Cancers;2024-04-26
3. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study;Journal of Thoracic Disease;2024-03
4. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report;Translational Lung Cancer Research;2024-03
5. Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer;Thoracic Cancer;2024-01-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3